EGFR mutation accounted for the majority of genetic alteration amongst our NSCLC population (49.7%), followed by KRAS mutation (3.6%), ALK fusion (3.4%), HER2 mutation (1.4%), ROS1 rearrangement (1.2%), and BRAF mutation (0.7%). This evidence concerns the gene KRAS and non-small cell lung carcinoma.